List of Excipients in Branded Drug ACYCLOVIR SODIUM

Generic Drugs Containing ACYCLOVIR SODIUM

Company	Ingredient	NDC	Excipient
AuroMedics Pharma LLC	acyclovir sodium	55150-154	WATER
ProPharma Distribution	acyclovir sodium	84549-155	WATER

What are the Most Frequently-Used Excipients in ACYCLOVIR SODIUM?

# Of NDCs	Excipient
2	WATER

Acyclovir Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Acyclovir sodium is an established antiviral active pharmaceutical ingredient used primarily in intravenous formulations for severe herpes simplex virus and varicella-zoster virus infections. The commercial opportunity is concentrated in formulation execution rather than new-molecule exclusivity. The strongest opportunities are ready-to-use presentations, improved storage stability, reduced preparation burden, pediatric dosing formats, and differentiated container-closure systems.

Acyclovir sodium has a narrow formulation margin. The product must maintain solubility at a high drug concentration, control pH, limit precipitation, manage sodium exposure, and remain compatible with intravenous fluids and infusion equipment. Excipients therefore influence product quality, hospital usability, regulatory risk, and lifecycle value.

What is acyclovir sodium and how is it formulated?

Acyclovir sodium is the injectable sodium salt of acyclovir, a guanine nucleoside analogue that inhibits herpesvirus DNA polymerase after intracellular phosphorylation. Intravenous products are used when oral administration is unsuitable or when infection severity requires parenteral therapy.

Commercial acyclovir sodium injections generally use a restrained excipient system:

Formulation component	Primary function	Commercial significance
Acyclovir sodium	Active ingredient	Determines concentration, sodium content, and solubility burden
Water for injection	Solvent	Supports sterile parenteral administration
Sodium hydroxide or equivalent alkali	pH adjustment and salt formation	Controls solubility and chemical stability
Hydrochloric acid or other acid	Final pH adjustment, where used	Enables tighter pH specification
Nitrogen or inert gas, where used	Headspace control	Can reduce oxidative stress during storage
Container-closure system	Protection and delivery	Affects adsorption, extractables, leachables, and shelf life

Many injectable acyclovir products are supplied as sterile powder requiring reconstitution or as a solution requiring dilution before infusion. Product-specific labels determine the approved concentration, diluent, storage period, infusion rate, and container requirements. DailyMed labeling for acyclovir sodium injection describes reconstitution and dilution requirements and warns against rapid intravenous administration because of renal toxicity risk.[1]

Acyclovir sodium is not a conventional opportunity for a complex excipient-loaded formulation. The active pharmaceutical ingredient itself creates the main formulation challenge. Excessive use of buffers, surfactants, or solubilizers can increase toxicity, compatibility, and regulatory burdens without providing a proportionate commercial benefit.

What excipient strategy best supports acyclovir sodium injection?

The preferred strategy is a minimal, tightly controlled excipient platform based on pH management, solvent quality, and container compatibility.

pH control

Acyclovir has limited aqueous solubility under conditions that do not favor ionization. Conversion to the sodium salt increases aqueous solubility, but the formulation remains sensitive to pH and concentration. The formulation should use the lowest effective alkali level and a narrow pH range that preserves solubility without creating excessive alkalinity.

A broad buffer system may be less attractive than direct pH adjustment because buffers can:

• Increase ionic strength.
• Alter compatibility with infusion solutions.
• Increase osmolality.
• Create additional degradation pathways.
• Complicate analytical and regulatory control.

The principal development objective is to establish a pH range that prevents precipitation during manufacture, dilution, refrigerated storage, and administration. The final specification should be supported by forced-degradation, freeze-thaw, dilution, and in-use studies under clinically relevant conditions.

Solubility and precipitation control

Precipitation is the central technical risk. Risk increases with high concentration, low temperature, unsuitable diluent, excessive dilution time, and contact with incompatible materials. Acyclovir sodium products require clear handling instructions because precipitated material can create a patient-safety concern and interrupt hospital use.

A formulation program should evaluate:

• Drug concentration at the point of manufacture and administration.
• Solubility across the proposed pH range.
• Dilution into 0.9% sodium chloride and compatible dextrose solutions.
• Refrigerated and room-temperature storage.
• Agitation and transport stress.
• Contact with polyvinyl chloride, polyolefin, glass, elastomer, and administration-set materials.
• Particulate formation after dilution.
• Compatibility with commonly used infusion devices.

The commercial value of a formulation that remains stable after dilution for a longer period is substantial. Hospitals can reduce pharmacy compounding waste, improve inventory management, and prepare doses earlier in the treatment cycle.

Sodium management

Acyclovir sodium contributes sodium to the final product. Sodium content is relevant for patients with renal impairment, fluid restrictions, cardiovascular disease, or other conditions requiring electrolyte management. The formulation should avoid unnecessary sodium-containing excipients and should provide transparent labeling of sodium exposure.

The development team should calculate sodium contribution from:

1. The acyclovir sodium salt.
2. Sodium hydroxide used in manufacture.
3. Sodium-containing buffers.
4. The final infusion diluent.

A low-excipient formulation can support a clearer clinical and regulatory profile. It does not eliminate the need for renal dosing and hydration controls, which remain important because acyclovir can cause renal toxicity when administered too rapidly or in patients with impaired renal function.[1]

Preservative strategy

Acyclovir sodium injection is generally better positioned as a preservative-free sterile product. Preservatives can create additional issues in intravenous use, including tolerability, neonatal restrictions, compatibility, and container-closure qualification.

A multidose presentation could reduce packaging cost, but it would require a robust preservative system, antimicrobial effectiveness data, and a risk assessment for repeated puncture. That tradeoff is usually unfavorable for an acutely administered antiviral intended for hospital use.

Antioxidant and chelator strategy

Routine addition of antioxidants or chelators should be justified by demonstrated degradation pathways. Acyclovir sodium development should first identify whether oxidation, trace metals, light, or container interaction drives product instability. If degradation is primarily pH- or temperature-dependent, antioxidants may add complexity without improving shelf life.

The preferred sequence is:

1. Establish degradation mechanisms.
2. Optimize pH and oxygen exposure.
3. Select a suitable container-closure system.
4. Add a chelator or antioxidant only when the benefit is demonstrated.
5. Confirm that the additive does not alter infusion compatibility or safety.

What formulations are protected or differentiated for acyclovir sodium?

The strongest differentiation opportunities are likely to arise from formulation and presentation claims rather than broad composition claims.

Ready-to-use premixed bags

A ready-to-use acyclovir sodium infusion could eliminate vial reconstitution and pharmacy dilution. The commercial benefits include lower preparation time, fewer manipulation steps, reduced exposure to compounding errors, and lower waste.

Key development requirements include:

• Long-term stability in the selected bag material.
• Compatibility with administration sets.
• Particulate control.
• Sterility assurance.
• Container-closure integrity.
• Defined in-use stability.
• Protection against accidental freezing or temperature excursions.

Potential patent claims could cover concentration, pH range, infusion solution, storage conditions, container material, or a combination of those features. The claims must be drafted narrowly enough to distinguish prior art but broadly enough to cover commercial manufacturing variants.

Lyophilized presentations

A lyophilized vial can improve solid-state stability and simplify global distribution where refrigerated liquid products are less practical. The opportunity depends on whether the active salt can be processed without damaging cake structure, reconstitution time, or chemical stability.

Relevant formulation variables include:

• Bulking agent selection.
• Collapse temperature.
• Residual moisture.
• Reconstitution volume.
• Reconstitution time.
• Cake appearance.
• Post-reconstitution precipitation.
• Stopper and vial compatibility.

Mannitol, sucrose, or other bulking and stabilizing agents may be evaluated, but each additive creates a new control strategy and must be justified for a sterile injectable product. A formulation patent based only on routine lyophilization excipients may face substantial obviousness risk.

Concentrated liquid formulations

A concentrated liquid could reduce shipping volume and support hospital pharmacy dilution. Its value depends on maintaining a clear solution across the labeled storage range and after dilution. Higher concentration also increases precipitation and osmolality risk, so the commercial advantage must be demonstrated against the added handling burden.

Pediatric and renal-dose presentations

Smaller vial sizes, lower-volume premixes, and dose-flexible presentations could address pediatric and renal-dose requirements. This opportunity is operational rather than molecular. A product that reduces dose measurement and dilution steps may have value even when the active ingredient and therapeutic indication are unchanged.

Potential differentiation includes:

• Small-volume ready-to-use syringes.
• Low-concentration bags for pediatric infusion.
• Unit-dose vials.
• Barcoded pharmacy presentations.
• Dose-banded hospital formats.
• Packaging designed for automated compounding systems.

What is the FDA regulatory status of acyclovir sodium?

Acyclovir sodium injection is an established small-molecule prescription product regulated through the FDA’s New Drug Application and Abbreviated New Drug Application pathways. Generic manufacturers generally pursue ANDA approval by demonstrating pharmaceutical equivalence and bioequivalence or meeting applicable waiver criteria for an injectable product.[2]

For a new formulation, the regulatory pathway depends on the extent of change:

Product strategy	Likely regulatory route	Principal evidence
Same strength, dosage form, route, and inactive ingredients as a reference product	ANDA	Pharmaceutical equivalence, product quality, manufacturing controls
Different excipient system or presentation with clinical or technical differentiation	505(b)(2) NDA may be relevant	Bridging, safety, stability, and product-specific justification
New ready-to-use container or infusion system	ANDA or 505(b)(2), depending on the change	Container compatibility, stability, administration performance
New therapeutic indication	NDA supplement or 505(b)(2), depending on rights and data	Clinical or bridging evidence
Compounded hospital preparation	Not an approved commercial pathway	Facility-specific compliance and compounding controls

FDA’s Inactive Ingredient Database can support excipient precedent analysis, but prior use in another injectable product does not automatically establish acceptability for a new concentration, route, or patient population.[3]

What is the Orange Book status and patent exposure?

Acyclovir sodium is a mature small-molecule product. The principal commercial barriers are unlikely to be original composition-of-matter patents. Risk is more likely to arise from product-specific patents, manufacturing claims, formulation patents, method-of-use patents, regulatory exclusivity, and supplier dependence.

The Orange Book should be reviewed for each current reference product and dosage form because listed patents and expiration dates can change. The analysis should distinguish:

• Active ingredient patents.
• Drug-product patents.
• Method-of-use patents.
• Pediatric exclusivity.
• Orphan-drug exclusivity, if applicable.
• Patent delisting or expiration events.
• Paragraph IV certifications in ANDA litigation.

FDA’s Orange Book provides the official listing framework for approved drug products and associated patent information.[4] Acyclovir sodium injectable products do not present a biosimilar issue because acyclovir is a chemically synthesized small molecule, not a biologic.

Paragraph IV challenges

A generic sponsor seeking approval before listed patent expiry may file a Paragraph IV certification. The commercial significance depends on whether the relevant patent covers:

• The injectable composition.
• A concentration or pH range.
• A premixed solution.
• A container or administration system.
• A method of treating a listed infection.
• A manufacturing process that is difficult to design around.

The absence of an obvious composition patent does not eliminate litigation risk. A formulation patent can delay approval or create launch constraints if the generic sponsor cannot certify that its product avoids the claimed features.

How strong is the acyclovir sodium patent estate?

The patent estate is likely strongest where a formulation solves a specific technical problem that is difficult to reproduce without using the claimed parameters. Stronger claim categories may include:

• Defined concentration and pH combinations that prevent precipitation.
• Long-term stability in a specified infusion bag.
• A ready-to-use product with validated in-use stability.
• A lyophilized cake with defined reconstitution performance.
• A container-closure system that controls adsorption or leachables.
• A manufacturing process that produces a narrow impurity profile.

Weaker claim categories include:

• Use of water for injection alone.
• Routine pH adjustment.
• Standard preservatives without unexpected performance.
• Conventional lyophilization with predictable excipients.
• Broad claims covering acyclovir sodium in any injectable solution.

Patent strength should be assessed using claim scope, written-description support, enablement, prior-art concentration, obviousness risk, design-around options, and actual commercial overlap. A technically valuable formulation may have limited blocking power if competitors can use a different pH, container, concentration, or reconstitution sequence.

Which companies could compete in acyclovir sodium injection?

Competition is typically fragmented among branded manufacturers, generic injectable companies, contract manufacturers, and regional hospital-supply providers. The relevant competitive set includes companies with:

• Sterile powder or liquid manufacturing capacity.
• FDA-approved injectable facilities.
• Access to acyclovir API.
• Experience with aseptic filling and lyophilization.
• Hospital distribution contracts.
• Premixed IV manufacturing capabilities.
• Regulatory registrations outside the United States.

The most defensible commercial position is not necessarily the lowest-cost vial. A supplier with reliable sterile capacity, resilient API sourcing, ready-to-use packaging, and low shortage exposure may obtain stronger hospital contracts than a supplier offering only price competition.

FDA drug-shortage records and product availability data should be monitored because sterile injectable markets can experience supply disruption from manufacturing deviations, facility interruptions, or component shortages.[5]

What commercial opportunities exist for acyclovir sodium?

The highest-value opportunities are operationally differentiated products:

Opportunity	Customer value	Main technical barrier
Ready-to-use IV bag	Removes reconstitution and dilution	Long-term bag stability and compatibility
Preservative-free unit-dose vial	Simplifies hospital inventory	Sterile manufacturing cost
Pediatric low-volume format	Reduces dose preparation error	Concentration and dosing flexibility
Extended post-dilution stability	Reduces pharmacy waste	Precipitation and chemical stability
Room-temperature liquid product	Simplifies logistics	Shelf-life and container interaction
Lyophilized global product	Improves transport robustness	Cycle development and reconstitution
Automated-compounding-compatible package	Supports hospital workflow	Device and container validation
Regional contract manufacturing	Reduces supply risk	Regulatory transfer and process comparability

Revenue exposure is concentrated in inpatient and hospital channels. Acyclovir sodium is less attractive as a high-growth branded product because oral acyclovir, valacyclovir, and other antiviral options address portions of the same therapeutic market. The injectable product retains value in severe infections, immunocompromised patients, neonatal care, and patients unable to take oral therapy.

How does acyclovir sodium compare with competing antiviral formulations?

Acyclovir sodium competes with oral acyclovir, oral valacyclovir, intravenous alternatives such as ganciclovir or foscarnet in selected indications, and hospital-prepared compounded solutions.

Attribute	Acyclovir sodium injection	Oral acyclovir	Valacyclovir
Route	Intravenous	Oral	Oral
Primary use	Severe or complicated infection	Less severe infection and suppression	Improved oral exposure and convenience
Formulation complexity	High sterile injectable burden	Lower	Lower
Hospital preparation risk	Material unless premixed	Low	Low
Renal management	Important	Important	Important
Excipient differentiation	High potential	More limited	More limited
Generic competition	Established	Established	Established

The injectable product’s commercial advantage is clinical and operational, not broad market exclusivity. A premixed or highly stable product can compete through workflow value even when the active ingredient is generic.

What manufacturing and IP barriers affect market entry?

The main entry barriers are sterile manufacturing, process validation, particulate control, API quality, container compatibility, and reliable supply. Acyclovir sodium manufacturing must control salt formation, pH, impurity levels, bioburden, endotoxin, and sterile filtration or aseptic processing parameters.

Manufacturing-focused IP may cover:

• Salt preparation.
• Crystallization conditions.
• Impurity reduction.
• Sterile filtration.
• Lyophilization cycles.
• Mixing order and pH adjustment.
• Filling and sealing.
• Container-closure systems.

A design-around assessment should test whether a competitor can change the excipient, concentration, pH, container, process order, or storage condition without losing product performance. If those alternatives are technically viable, the patent estate may have limited exclusionary power even when the marketed product is successful.

Key Takeaways

• Acyclovir sodium is a mature injectable antiviral with limited new-molecule exclusivity.
• The optimal excipient strategy is usually minimal: acyclovir sodium, water for injection, and controlled pH adjustment.
• Solubility, precipitation, sodium exposure, renal safety, and infusion compatibility are the central formulation constraints.
• Ready-to-use bags, pediatric presentations, unit-dose formats, and extended post-dilution stability offer the clearest commercial opportunities.
• Formulation patents are more relevant than composition-of-matter patents for new commercial products.
• FDA Orange Book review is required for current listed patents, expiration dates, and Paragraph IV exposure.
• Acyclovir sodium has no biosimilar pathway because it is a chemically synthesized small molecule.
• Sterile manufacturing capacity and hospital distribution are major barriers to entry.
• Commercial differentiation depends on preparation efficiency, stability, supply reliability, and packaging rather than active-ingredient novelty.

FAQs

Can acyclovir sodium be formulated without preservatives?

Yes. A preservative-free sterile vial, lyophilized product, or single-use premixed bag is generally the more commercially defensible strategy for intravenous use. The product must rely on validated aseptic processing, container-closure integrity, and single-use handling controls.

Which excipient is most important in acyclovir sodium injection?

The pH-adjusting system is the most important excipient element because pH directly affects salt form, solubility, precipitation risk, and stability. Water for injection is the principal solvent, while additional buffers or stabilizers require product-specific justification.

Is a ready-to-use acyclovir sodium bag patentable?

Potentially. Patentability would depend on the specific combination of concentration, pH, infusion vehicle, storage condition, container material, stability profile, and manufacturing process. A generic claim to a premixed acyclovir sodium bag would face substantial prior-art and obviousness scrutiny.

Does acyclovir sodium require refrigerated storage?

Storage requirements vary by product, concentration, container, and approved label. A formulation intended for room-temperature storage must demonstrate chemical stability, physical stability, sterility, particulate control, and container compatibility over the proposed shelf life.

What is the most attractive licensing opportunity in acyclovir sodium?

The strongest licensing opportunity is a validated ready-to-use or extended-stability injectable platform with regulatory support, sterile manufacturing capacity, and hospital distribution. API-only licensing is less differentiated than a complete formulation and packaging solution.

References

1. DailyMed. (n.d.). Acyclovir sodium injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2019). ANDA submissions: Content and format. https://www.fda.gov/drugs

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveIngredient

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (n.d.). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/stockcheck.cfm

6. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/

7. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. https://www.ich.org/